280 related articles for article (PubMed ID: 28791662)
1. Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals.
Zhuang Y; Qiu X; Wang L; Ma Q; Mapstone M; Luque A; Weber M; Tivarus M; Miller E; Arduino RC; Zhong J; Schifitto G
J Neurovirol; 2017 Oct; 23(5):704-712. PubMed ID: 28791662
[TBL] [Abstract][Full Text] [Related]
2. Effects of HIV and combination antiretroviral therapy on cortico-striatal functional connectivity.
Ortega M; Brier MR; Ances BM
AIDS; 2015 Mar; 29(6):703-12. PubMed ID: 25849834
[TBL] [Abstract][Full Text] [Related]
3. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.
Winston A; Duncombe C; Li PC; Gill JM; Kerr SJ; Puls R; Petoumenos K; Taylor-Robinson SD; Emery S; Cooper DA;
Clin Infect Dis; 2010 Mar; 50(6):920-9. PubMed ID: 20146627
[TBL] [Abstract][Full Text] [Related]
4. Changes in functional connectivity in people with HIV switching antiretroviral therapy.
Toniolo S; Cercignani M; Mora-Peris B; Underwood J; Alagaratnam J; Bozzali M; Boffito M; Nelson M; Winston A; Vera JH
J Neurovirol; 2020 Oct; 26(5):754-763. PubMed ID: 32500477
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial toxicity before and after combination antiretroviral therapy, a Magnetic Resonance Spectroscopy study.
Tivarus ME; Zhuang Y; Wang L; Murray KD; Venkataraman A; Weber MT; Zhong J; Qiu X; Schifitto G
Neuroimage Clin; 2021; 31():102693. PubMed ID: 34020161
[TBL] [Abstract][Full Text] [Related]
6. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B;
HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457
[TBL] [Abstract][Full Text] [Related]
7. Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial.
Winston A; Stöhr W; Antinori A; Amieva H; Perré P; De Wit S; Reynes J; Gompels M; dʼArminio Monforte A; Gatell JM; Grarup J; Pozniak A; Babiker A; Raffi F; Richert L;
J Acquir Immune Defic Syndr; 2017 Feb; 74(2):185-192. PubMed ID: 27749603
[TBL] [Abstract][Full Text] [Related]
8. Evolution of changes in cognitive function after the initiation of antiretroviral therapy.
Mora-Peris B; Stevens E; Ferretti F; Underwood J; Taylor S; Winston A
AIDS Res Ther; 2016; 13():20. PubMed ID: 27081393
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Winston A; Puls R; Kerr SJ; Duncombe C; Li PC; Gill JM; Taylor-Robinson SD; Emery S; Cooper DA;
HIV Med; 2012 Apr; 13(4):245-51. PubMed ID: 22151608
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
Vera JH; Jackson A; Dickinson L; Else L; Barber T; Mora-Peris B; Back D; Boffito M; Winston A
HIV Clin Trials; 2015; 16(1):39-42. PubMed ID: 25777188
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic network connectivity abnormalities in HIV-infected individuals over age 60.
Guha A; Wang L; Tanenbaum A; Esmaeili-Firidouni P; Wendelken LA; Busovaca E; Clifford K; Desai A; Ances BM; Valcour V
J Neurovirol; 2016 Feb; 22(1):80-7. PubMed ID: 26265137
[TBL] [Abstract][Full Text] [Related]
12. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
[TBL] [Abstract][Full Text] [Related]
13. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort.
Rokx C; Fibriani A; van de Vijver DA; Verbon A; Schutten M; Gras L; Rijnders BJ;
Clin Infect Dis; 2015 Jan; 60(1):143-53. PubMed ID: 25273080
[TBL] [Abstract][Full Text] [Related]
14. Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
González-García J; Cohen D; Johnson M; Sloan L; Fredrick L; Naylor C; da Silva B; Bernstein B;
AIDS Res Hum Retroviruses; 2010 Aug; 26(8):841-5. PubMed ID: 20672994
[TBL] [Abstract][Full Text] [Related]
15. Neuronal-Glia Markers by Magnetic Resonance Spectroscopy in HIV Before and After Combination Antiretroviral Therapy.
Sailasuta N; Ananworanich J; Lerdlum S; Sithinamsuwan P; Fletcher JL; Tipsuk S; Pothisri M; Jadwattanakul T; Jirajariyavej S; Chalermchai T; Catella S; Busovaca E; Desai A; Paul R; Valcour V;
J Acquir Immune Defic Syndr; 2016 Jan; 71(1):24-30. PubMed ID: 26258565
[TBL] [Abstract][Full Text] [Related]
16. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Sculier D; Gayet-Ageron A; Battegay M; Cavassini M; Fehr J; Hirzel C; Schmid P; Bernasconi E; Calmy A;
BMC Infect Dis; 2017 Jul; 17(1):476. PubMed ID: 28683720
[TBL] [Abstract][Full Text] [Related]
17. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
18. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
[TBL] [Abstract][Full Text] [Related]
19. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
20. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
